Chair Duguid and members of the committee, thank you very much for the opportunity to join you here today.
My name is Evan Cameron, and I'm the manager of public affairs and communications at the Canadian Nuclear Isotope Council. As the voice of Canada's isotope sector, the CNIC represents 130 leading organizations across Canada's nuclear industry, as well as in academia and health care. As this committee undertakes its study on Canada's nuclear future, it is critical that Canada's growing isotope ecosystem be part of the conversation.
Canada has a long history of isotope innovation. From the world's first cancer treatment using cobalt-60—which took place in London, Ontario, back in 1951—to the innovative production of dozens of emerging isotopes in our fleet of CANDU power reactors, along with McMaster's research reactor and our network of cyclotrons from coast to coast, we have a strong foundation to build upon.
Today, our industry is at a critical moment. With a strong track record and a rapidly growing nuclear medicine market, Canada has a fresh opportunity to cement its leadership as an isotope innovator. In its nuclear energy strategy for Canada, the government committed to the development of a comprehensive radioisotope strategy—something the CNIC has advocated since its inception. We're glad to see this first important step.
At this important juncture, there are several key opportunities for the Government of Canada to unlock growth across the isotope ecosystem.
First, the nature of Canada's isotope industry means that it operates at the intersection of several federal departments and regulators. The forthcoming strategy should establish the foundation for a coordinated, long-term federal approach to fostering isotope innovation, with consideration for the rapid pace of advancement within the sector.
Secondly, the radioisotope strategy should be informed by a broad group of experts, potentially through an advisory council, in order to help Natural Resources Canada achieve its goal of growing Canada's share of the global medical isotope market by at least 10% while enabling sector-wide implementation of this strategy.
Beyond the development of the radioisotope strategy, there are several other levers the federal government can pull to catalyze growth, attract investment and save lives. These levers include expanding access to federal financing through the Canada Infrastructure Bank, for example, broadening eligibility under relevant clean-technology investment tax credits to support isotope-related infrastructure and production, investing in workforce development, supporting access to talent, and modernizing assessment procedures through Canada's drug agency.
More directly, the federal government can strengthen Canada's radiopharmaceutical pipeline by renewing and expanding support for the ISED-funded Canadian Medical Isotope Ecosystem initiative, which has supported more than a dozen projects from coast to coast since 2023. This initiative has enabled more than 60,000 additional patient doses while catalyzing over $278 million in follow-on investment—an 8:1 ratio of follow-on investment to ISED's initial $35-million contribution.
Canada's isotope sector also sees significant potential for growth beyond medicine, with important applications for Canadian-produced isotopes in agriculture, construction, quantum technologies, fusion, non-destructive testing and even radioisotope power systems used to power deep-space exploration. Canada's isotope sector illustrates the broader value of our nuclear industry. From the research legacy of Chalk River to the CANDU fleet that supports commercial-scale isotope production today, Canada's nuclear capabilities provide a foundation for innovation well beyond electricity generation. With isotope and radiopharmaceutical innovation hubs emerging across the country, continued investment in production and clinical infrastructure, and support across party and jurisdictional lines, Canada's isotope sector is well placed to build on this global legacy.
All of us are affected by cancer, and its impacts are far-reaching. As this committee considers Canada's nuclear future, it is important to recognize our sector's role in providing hope to patients and families globally. By investing in Canada's nuclear isotope supply chain, we can advance next-generation diagnostics and cancer therapies, supply critical isotopes for industrial and advanced technology applications, and catalyze investments in our community. When you think of Canada's nuclear future, think of hope. That is our legacy.
Thank you for your time. I'm happy to take your questions.
